STOCKWATCH
·
Medical/Dental Instruments
Quarterly ResultMay 5, 2026, 07:02 AM

Embecta Lowers FY26 Guidance, Cuts Dividend to $0.01, Authorizes $100M Buyback

AI Summary

Embecta Corp. reported disappointing second quarter fiscal year 2026 financial results, with revenues down 14.4% to $221.8 million and a net loss of $(4.1) million. The company significantly lowered its full-year 2026 financial guidance, citing increased competitive dynamics and softness in U.S. market volumes. In response, Embecta initiated a review of its cost structure, authorized a three-year $100 million share repurchase program, and reduced its quarterly dividend from $0.15 to $0.01 per share. The acquisition of Owen Mumford is still on track to close in May 2026.

Key Highlights

  • Q2 FY2026 revenues were $221.8 million, a 14.4% decrease year-over-year.
  • The company reported a Q2 FY2026 net loss of $(4.1) million, compared to $23.5 million net income in prior year.
  • Adjusted diluted EPS for Q2 FY2026 was $0.27, down from $0.70 in the prior year period.
  • Fiscal year 2026 revenue guidance lowered to $1,015-$1,035 million from $1,071-$1,093 million.
  • Fiscal year 2026 adjusted EPS guidance lowered to $1.55-$1.75 from $2.80-$3.00.
  • Board authorized a three-year $100 million share repurchase program.
  • Quarterly cash dividend reduced from $0.15 to $0.01 per share.
  • Acquisition of Owen Mumford is anticipated to be complete during May 2026.
EMBC
Medical/Dental Instruments
Embecta Corp.

Price Impact